Samsung applies Europe approval of ‘SB5,’ third biosimilar

On the 18^th, Samsung Bioepis(CEO Han-seung Ko) announced application of the sales approval of the ‘Humira’ biosimilar, ‘SB5,’ to the EMA(European Medicines Agency).

SB5, the Samsung Bioepis’s third biosimilar product, is a U.S. Abbbies’s Humira biosimilar which recorded approximately KRW 16 trillion last year.

Currently, the world’s most selling anti-TNFα products are adalimumab, infliximab a...